NDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
9
Data completeness
5/8 — Partial
SIMBRINZA (brinzolamide/brimonidine tartrate) by Alcon is carbonic anhydrase inhibitors [moa]. First approved in 2013.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMBRINZA is a fixed-dose combination ophthalmic suspension containing brinzolamide (a carbonic anhydrase inhibitor) and brimonidine tartrate, approved by the FDA on April 19, 2013. The product is indicated for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works through dual mechanisms: brinzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while brimonidine acts as an alpha-2 adrenergic agonist. SIMBRINZA represents a convenient combination therapy option in the glaucoma treatment landscape, eliminating the need for separate instillations of two agents.
$0.1BPart D
4.5 years to LOEMechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Carbonic Anhydrase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
Started Jun 2016
173 enrolled
Open-angle GlaucomaOcular Hypertension
24-hr Intraocular Pressure Control With SIMBRINZA ®
Started May 2016
162 enrolled
Glaucoma
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
Started Aug 2015
290 enrolled
Open-Angle GlaucomaOcular Hypertension
A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
Started Nov 2014
150 enrolled
Open-Angle GlaucomaOcular Hypertension
The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure
Started Aug 2014
60 enrolled
Open Angle GlaucomaOcular HypertensionPigment Dispersion Syndrome+1 more
Worked on SIMBRINZA at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.